Problems › Our Sales Cycle Is Too Long › Healthcare Providers
Long cycles are usually the provider failing to build an internal case on cost per episode for the 38,000 attributed lives, not the seller failing to persuade. The version of this question that applies to healthcare providers is not the generic one. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — so an answer that ignores cost per episode will be confidently wrong. The analysis has to start from payer mix and panel size rather than from revenue.
Long cycles are usually the provider failing to build an internal case on cost per episode for the 38,000 attributed lives, not the seller failing to persuade. The version of this question that applies to healthcare providers is not the generic one. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — so an answer that ignores cost per episode will be confidently wrong. The analysis has to start from payer mix and panel size rather than from revenue.
A cycle that runs long is rarely stalled on interest in the value-based contract. It is stalled at a specific point — a stage where the deal consistently sits — and that point is normally where the champion has to justify the decision on panel size and payer mix to the CFO or medical director who was never in the room.
Which reframes the fix. Shortening a cycle is mostly a matter of giving the champion the material to win an argument you are not present for: the cost per episode projection, the risk answer against downside on attributed lives, the comparison against doing nothing under the current payer mix.
The other frequent cause is selling to someone who cannot authorise the spend on the value-based contract. That does not lengthen the cycle so much as add a hidden one at the end.
These three together are the signature. One on its own usually points somewhere else.
✓ Opportunities sit for weeks in the same stage without updated cost per episode modeling moving to the CFO or medical director.
✓ Forecast dates slip repeatedly on the same opportunities tied to attributed lives under value-based contracts.
✓ The main competitor in lost deals is no decision on the value-based contract after contribution per provider is reviewed.
The move that usually makes it worse. Adding follow-up activity, which increases pressure on the champion without giving them anything new to take to the decision-maker on cost per episode.
It is for you if you run or finance a healthcare provider and deals consistently stall at the same stage. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a healthcare provider. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Turn $6.8 M downside-risk liability into a $22–35 M licensing platform within 36 months.
The leak it closes. Eliminates $6.8 M downside exposure by enabling proactive utilization management.
The assumption it rests on. Cost-measurement platform achieves <5 % variance versus manual abstraction within 12 months — the engine put the probability at 0.75.
| Investment required | $2.1–3.5 M over 36 months |
| Expected return | 6.3–16.7× cash-on-cash within 36 months based on $196 M current revenue base. |
| Revenue, year 1 | $0 licensing revenue; $1.8 M internal cost avoidance |
| Revenue, year 2 | $4.2 M licensing ARR (40 physicians × $120K + 5 external practices × $400K) |
| Revenue, year 3 | $13.5 M licensing ARR (90 physicians × $120K + 18 external practices × $400K) plus $4–8 M shared-savings upside |
| Exit criteria | Terminate platform investment if variance exceeds 8 % by Month 18 OR if fewer than 40 physicians sign licensing agreements by Month 24; redeploy remaining capital to ASC surgeon-retention track. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Go-to-Market & Commercial Strategy, one of 29 engagements the platform runs. For healthcare providers it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
Find the stage where deals sit longest and work out what the buyer has to do there. It is almost always an internal approval, and the fix is material rather than persuasion.
It compresses the last step and does nothing to the stalls earlier in the cycle, which is where the time actually goes. It also teaches buyers that waiting is rewarded.
No, if the deal size and win rate justify it. It becomes a problem when the cycle is longer than your cash conversion allows, which is a financing constraint rather than a sales one.
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית